Obesity Clinical Trials in San Antonio

Showing 61-80 of 152 trials

A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

NCT06703021

Phase 2 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of various aleniglipron (GSBR-1290) dose regimens compared with placebo in participants living with obesity or overweight with ≥ 1 weight-related comorbidity, in addition to diet and exercise, over a 44-week period.

ObesityOverweightChronic Weight Management

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics82 participantsStarted Dec 2024

Glendale, California, United States • Montclair, California, United States • Valparaiso, Indiana, United States +7 more locations

TERMINATEDPhase 2< 1 mile

A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes

NCT07030868

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of treatment with LY3549492 compared to placebo in adult participants with obesity or who are overweight with type 2 diabetes. Participation in the study will last about 11 months.

ObesityOverweightType 2 Diabetes

Eli Lilly and Company1 participantsStarted Jun 2025

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • Greenbrae, California, United States +39 more locations

A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes

Obesity Trials in Other Cities

A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway

A Study of LY3541105 in Healthy and Overweight Participants

A Study on How NNC0174-1213 Works in People With Overweight or Obesity.

Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

Pediatric Obesity Weight Evaluation Registry (POWER) Study

Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions

Cardiovascular Risk Screening and Risk Reduction in Women Vets

A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial

Postextubation Use of Noninvasive Respiratory Support in Severely Obese Patients

The EMBER Trial for Weight Management Engagement

Spatz3 Adjustable Balloon System® (Spatz3) Post Approval Study

Greenlight Plus Study: Approaches to Early Childhood Obesity Prevention

Open-Label Extension Study of Setmelanotide

Long Term Extension Trial of Setmelanotide

A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or Obese

Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With Obesity

Other Conditions in San Antonio